Is NCT04390724 recruiting in Chicago, IL?

Yes, NCT04390724 is currently recruiting participants at its Chicago, IL location. This hcc clinical trial is actively enrolling qualified participants.

How do I join the hcc clinical trial in Chicago?

To join this clinical trial in Chicago, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Chicago clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

HCC Clinical Trial in Chicago, IL

About This HCC Study in Chicago

HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.

Sponsor: Northwestern University

Who Can Participate

Inclusion Criteria

Patients must have been diagnosed with HCC confirmed by histology or must meet one of the following American Association for the Study of Liver Diseases (AASLD) guidelines:

AFP \>200 and radiological evidence (arterial hypervascularity) of lesion \> 2 cm does not require biopsy

Two imaging modalities (triphasic CT, MRI, ultrasound, angiography) demonstrating arterial hypervascularity in the background of cirrhosis does not require biopsy

One imaging modality with a lesion with arterial hypervascularity with wash out in early or delayed venous phase, does not require a biopsy

Child-Pugh stage A

Future Liver Remnant (FLR) of \< 40%

ECOG Performance Status 0-1

Bilirubin ≤ 3.0 mg/dl- Treatment may proceed if the Bilirubin is elevated if the tumor may be isolated from a vascular standpoint

Creatinine ≤ 2.0 mg/dl

ANC ≥ 1.5 K/uL

Platelets \> 25 K/uL

Patient is willing participate in this study and has signed the consent

For Group 2 patients only:

Patients planned Y90 dose and embolic load is found to fall within the optimal dose and embolic load size from data from Group 1 patients

Exclusion Criteria

Patient must not be pregnant NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

Has not undergone a hysterectomy or bilateral oophorectomy

Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \> 12 months)

For Patients in Group 2 only:

Patients who have contraindications to MRI:

Patients that are claustrophobic and haven't been able to tolerate an MRI in the past. (Patients with mild claustrophobia are eligible and have the option to take 1mg oral Lorazepam prior to the MRI, if needed)

Allergy to gadolinium-containing contrast media

Patients with a pacemaker, metallic clip, aneurysm clips, shrapnel fragments, etc.

Patients with an eGFR \< 30 mL/min/m²

Must not have any significant life-threatening extra-hepatic disease or life- threatening secondary malignancies, including patients who are on dialysis, have unresolved diarrhea, have serious unresolved infections including patients who are known to be HIV positive or have acute HBV or HCV

Must not have any contraindications to angiography and selective visceral catheterization such as bleeding diathesis or coagulopathy that is not correctable by usual therapy of hemostatic agents (e.g. closure device)

Must not have any co-morbid disease or condition that would place the patient at undue risk and preclude safe use of TheraSphere treatment, in the Investigator's judgment

History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically \-

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT04390724) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

HCC Treatment Options in Chicago, IL

If you're searching for hcc treatment options in Chicago, IL, this clinical trial (NCT04390724) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hcc specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hcc clinical trials near you to find additional studies recruiting in your area.

HCC Clinical Trial in Chicago, IL

Expert Care in Chicago

IRB Approved

No-Cost Care

Apply for This Chicago Location

Why Participate?

Simple Process